Ocugen, Inc. (OCGN) Revenue by Segment & Business Profile
Gene therapy product candidates for inherited retinal diseases to healthcare providers was 100.0% of Ocugen, Inc.'s revenue, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
OCGNOcugen, Inc.Follow OCGN — free
—
Price chart with a free account
- Market cap
- 250.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
What the company does
Ocugen, Inc. is a biotechnology company in the healthcare sector. Trailing twelve-month revenue: $4.6 million as of 2026-06-30.
Roles we read
from the filings, not the sector label- Clinical-stage developer
Ocugen, Inc. — questions
- What does Ocugen, Inc. do?
- Ocugen, Inc. is a biotechnology company in the healthcare sector. Trailing twelve-month revenue: $4.6 million as of 2026-06-30.
- How does Ocugen, Inc. make money?
- By the lines it reports in its SEC filings: Gene therapy product candidates for inherited retinal diseases to healthcare providers 100.0% of revenue.
Every figure on this page comes from Ocugen, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.